John McAdory
Chief Operating OfficerMr. John McAdory is Chief Operating Officer of Oncolytics Biotech Inc. from June 1, 2026. He oversees the Oncolytics Biotech’s clinical operations and development activities, preclinical research and development efforts and play a key role in strategic partnerships and broader business development initiatives. He was Executive Vice President of Strategy & Operations at Oncolytics Biotech Inc. from January 2026 to June 2026. He has extensive experience leading late-stage oncology programs, particularly in the oncolytic virus space. From January 2020 to January 2026, Mr. McAdory served as Vice President, Clinical Operations at CG Oncology, Inc. (Nasdaq: CGON), where he led clinical operations through its pivotal Phase 3 program and initial public offering. From February 2018 to January 2020, Mr. McAdory served as Head of Clinical Operations at SillaJen, Inc. Earlier in his career, Mr. McAdory held clinical operations positions at UCB and Amgen Inc. Mr. McAdory holds a Master of Health Administration from the University of North Carolina at Chapel Hill and a Bachelor of Science in Biology from Hampton University.
Positions
- Company NameOncolytics Biotech Inc.Stock CodeONCYPositionChief Operating OfficerColleagues
- JKJared KellyCEO & Director
- WFWayne F. PisanoChairman of the Board
- KJKirk J. LookChief Financial Officer
- TCThomas C. HeinemanChief Medical Officer
- AHAllison HagermanChief Technology Officer
- AFAngela Frances HolthamIndependent Director
- DMDeborah M. BrownIndependent Director
- JMJonathan M. N. RigbyIndependent Director
